Comparative Pharmacology
Head-to-head clinical analysis: ATELVIA versus FOSAMAX PLUS D.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATELVIA versus FOSAMAX PLUS D.
ATELVIA vs FOSAMAX PLUS D
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Risedronate (the active ingredient in ATELVIA) inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and inhibiting the mevalonate pathway, which prevents farnesyl pyrophosphate synthase activity, leading to disruption of osteoclast function and induction of apoptosis.
Alendronate, a bisphosphonate, inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite and interfering with the mevalonate pathway, leading to osteoclast apoptosis. Cholecalciferol (vitamin D3) promotes intestinal calcium absorption and bone mineralization.
35 mg orally once weekly on the same day each week, taken with at least 240 mL of plain water at least 30 minutes before the first food, beverage, or medication of the day. Do not crush, chew, or suck tablets.
One tablet (alendronate 70 mg / cholecalciferol 2800 IU) orally once weekly.
None Documented
None Documented
Terminal elimination half-life is approximately 10 days due to prolonged bone binding and slow release; clinical suppression of bone resorption persists for weeks after discontinuation.
Alendronate: Terminal half-life in bone is estimated at 10+ years due to slow release from the skeleton. Cholecalciferol: Half-life of 25-hydroxyvitamin D is ~15 days.
Approximately 50% of absorbed dose excreted renally unchanged; remainder eliminated via biliary/fecal routes. Renal clearance correlates with creatinine clearance.
Alendronate: ~50% excreted unchanged in urine; remainder is taken up by bone and slowly eliminated. No biliary or fecal excretion of intact drug. Cholecalciferol: ~50% excreted in bile via feces; less than 1% in urine.
Category C
Category C
Bisphosphonate
Bisphosphonate